ICER evaluates medical treatments, drug pricing, and health care access through independent evidence-based assessments and policy research

The Institute for Clinical and Economic Review (ICER) conducts independent evaluations of medical tests, treatments, and delivery systems to inform health care affordability, access, and fair pricing. Its work includes assessments of treatment-resistant depression, Huntington’s disease, Friedreich’s ataxia, hypertension, Parkinson’s disease, and specific drugs under Medicare price negotiation. ICER also publishes policy research on FDA accelerated approval, launch prices for drugs approved between 2022 and 2025, and cost-effectiveness methods including the evLY and QALY. The supplied material highlights reported impact such as New York Medicaid savings exceeding $500 million and engagement with more than 600 patient groups and representatives. It also describes a clinical trial diversity rating tool and ongoing public comment processes for draft reports.